Skip to main content
SpringerLink
Log in

Protection against cisplatin-induced nephrotoxicity by recombinant human erythropoietin

  • Original Article
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Cisplatin (CDDP) is a potent nephrotoxin, and nephrotoxicity is its most important dose-limiting toxicity. In this study, we aimed to investigate the role of recombinant human erythropoietin (rhEPO) in the protection of cisplatin-induced nephrotoxicity and compare its efficacy with the cell-protective agent amifostine. All experiments were conducted on female Wistar albino rats. Animals were randomly assigned to four groups, each including six rats. Group A received only CDDP, group B received CDDP plus rhEPO, group C received CDDP plus amifostine, and group D received only rhEPO. At the end of 7 wk, hemoglobin (Hgb), hematocrite (Htc), blood urea nitrogen (BUN), and creatinine (Cr) levels were determined and kidneys of the rats were removed. The weights of the kidneys were measured and sent for histopathological examination. Proximal tubules from four areas of the kidney (outer cortex, inner cortex, the medullary ray, and outer stripe of outer medulla [OSOM]) were evaluated. There were statistically significant differences among the groups in terms of tubular scores, including overall renal tubular score, cortex, inner cortex, OSOM, and medullary ray tubular scores, and Htc levels. Group A rats had the worse tubular scores in all categories when compared to group D rats. When the results of groups B and C were compared, there were no differences in terms of BUN, Cr levels, and tubular scores, but the Htc level was significantly higher in group B. Group B rats had better overall and OSOM tubular scores when compared to group A. Group C also had better overall and OSOM tubular scores compared to group A. The present study showed for the first time that rhEPO plays an important role in the prevention of cisplatin-induced nephrotoxicity and it is as effective as amifostine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Anand, A.J. and Bashey, B. (1993). New insights into cisplatin nephrotoxicity. Ann. Pharmacother. 27:1519–1525.

    PubMed  CAS  Google Scholar 

  2. Aggarwal, S.K. (1993). A histochemical approach to the mechanism of action of cisplatin and its analogs. J. Histochem. Cytochem. 41:1053–1073.

    PubMed  CAS  Google Scholar 

  3. Jones, T.W., et al. (1985). Cis-diamminedichloroplatinum (II)-induced acute renal failure in the rat. Lab. Invest. 52:363–374.

    PubMed  CAS  Google Scholar 

  4. Zhou, H., et al. (1999). Attenuation of cisplatin-induced acute renal failure is associated with less apoptotic cell death. J. Lab. Clin. Med. 134:649–658.

    Article  PubMed  CAS  Google Scholar 

  5. Noncleco, D., et al. (1989). Tissue injury and repair in the rat kidney after exposure to cisplatin or carboplatin. Exp. Mol. Pathol. 51:123–140.

    Article  Google Scholar 

  6. Spencer, C.M. and Goa, K.L. (1995). Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector. Drugs 50:1001–1031.

    Article  PubMed  CAS  Google Scholar 

  7. Maxwell, P.H., et al. (1997). Sites of erythropoietin production. Kidney Int. 51:303–401.

    Article  Google Scholar 

  8. Yalcin, S. and Orhan, B. (1998). Recombinant human erythropoietin in the treatment of chronic anemia of cancer. Acta Hematol. (Basel) 100:115–115.

    CAS  Google Scholar 

  9. Orhan, B. and Yalcin, S. (1999). What are patients willing to pay for prophylactic epoetin alfa. A cost-benefit analysis. Cancer 86:1095–1096.

    Article  PubMed  CAS  Google Scholar 

  10. Orhan, B., et al. (1998). Does cisplatin stimulate erythropoietin secretion from the peritubuler cell of the kidney? Clin. Nephrol. 50:202–203.

    PubMed  CAS  Google Scholar 

  11. Westenfelder, C., et al. (1999). Human, rat and mouse kidney cells express functional erythropoietin receptors. Kidney Int. 55:808–820.

    Article  PubMed  CAS  Google Scholar 

  12. Westenfelder, C. and Baranowski, R.L. (2000). Erytropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int. 58:647–657.

    Article  PubMed  CAS  Google Scholar 

  13. Ikegaya, N., et al. (1999). High expression of erythropoietin receptor in human chronic progressive glomerulonephritis. Kidney Int. 55:1159–1160.

    Article  Google Scholar 

  14. Yalcin, S., et al. (1996). Granulocyte-colony stimulating factor (G-CSF) administration for chemotherapy induced neutropenia. Hematology 1:155–162.

    CAS  Google Scholar 

  15. Spaeth, D., et al. (1999). Updating 1999 of standarts, options and recommendations (SOR) for the clinical use of erythropoietin in oncology. Bull. Cancer 86:631–639.

    PubMed  CAS  Google Scholar 

  16. Bennett, C.L., et al. (1999). Use of hematopoietic colony-stimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. J. Clin. Oncol. 17:3676–3681.

    PubMed  CAS  Google Scholar 

  17. Vaziri, N.D., et al. (1994). Erythropoietin enhances recovery from cisplatin induced acute renal failure. Am. J. Physiol. 266:360–366.

    Google Scholar 

  18. Bagnis, C., et al. (2001). Erythropoietin enhances recovery after cisplatin induced acute renal failure in rat. Nephrol. Dial. Transplant. 5:932–938.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Oncology, School of Medicine, Turkey

    Suayib Yalcin

  2. Department of Histology and Embryology, Hacettepe University, Ankara, Turkey

    Sevda Müftüoğlu & Dilara Zeybek

  3. Department of Radiation Oncology, Hacettepe University, Ankara, Turkey

    Eren Cetin & Berna Akkuş Yildirim

  4. Department of Internal Medicine, Hacettepe University, Ankara, Turkey

    Banu Şarer

  5. Ali Osman Sönmez Oncology Hospital, Ankara, Turkey

    Bülent Orhan

Authors
  1. Suayib Yalcin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sevda Müftüoğlu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eren Cetin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Banu Şarer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Berna Akkuş Yildirim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Dilara Zeybek
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Bülent Orhan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Suayib Yalcin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yalcin, S., Müftüoğlu, S., Cetin, E. et al. Protection against cisplatin-induced nephrotoxicity by recombinant human erythropoietin. Med Oncol 20, 169–173 (2003). https://doi.org/10.1385/MO:20:2:169

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1385/MO:20:2:169

Key Words

Search

Navigation